Federal Court Grants First Amendment Injunction in Amarin Case
National Law Review
Florham Park partner Ken Wilbur authored “Federal Court Grants First Amendment Injunction in Amarin Case,” for Life Sciences Now, which was republished by the National Law Review. A decision handed down in the Southern District of New York granted Amarin Pharma’s request for a preliminary injunction barring the FDA from pursuing misbranding actions against Amarin. The decision confirms the Caroina standing that the government cannot prosecute pharmaceutical manufacturers or their representatives under the FDCA for speech which promotes lawful, off-label use of an FDA-approved drug.
In this article, Ken examines the history behind the cases, and what this decision might mean for the pharmaceutical industry going forward.
Read “Federal Court Grants First Amendment Injunction in Amarin Case.”
The material contained in this communication is informational, general in nature and does not constitute legal advice. The material contained in this communication should not be relied upon or used without consulting a lawyer to consider your specific circumstances. This communication was published on the date specified and may not include any changes in the topics, laws, rules or regulations covered. Receipt of this communication does not establish an attorney-client relationship. In some jurisdictions, this communication may be considered attorney advertising.
Meet the Authors
